Skip to Content

V920 Approval Status

FDA Approved: No
Brand name: V920
Generic name: rVSV∆G-ZEBOV-GP, live attenuated
Company: Merck
Treatment for: Ebola Zaire Disease Prophylaxis

V920 (rVSV∆G-ZEBOV-GP, live attenuated) is an investigational vaccine for Ebola Zaire disease.

Development Status and FDA Approval Process for V920

DateArticle
Nov 13, 2018Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide